secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0000879169-26-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q1 revenue $1.27B (+21% YoY), Non-GAAP EPS $1.81 beats prior $1.16; pipeline expands
--------------------------------------------------------------------------------

- Total net sales $1.10B (+20% YoY); Jakafi $758M (+7%), Opzelura $143M (+20%), Hem/Onc $204M (+116%).
- GAAP net income $303M ($1.47 diluted EPS) vs $158M ($0.80) prior year; Non-GAAP diluted EPS $1.81.
- Positive Phase 3 vitiligo results for povorcitinib; NDA accepted for HS; four product approvals/launches expected in next 12 months.
- Appointed Suketu Upadhyay as CFO effective May 4, 2026; cash position $4.0B.
- FY 2026 guidance reaffirmed: total net sales $4.77-$4.94B; R&D and SG&A expenses guided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/0000879169-26-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/incy-20260428.htm
  HTML page:      https://secwatch.observer/filing/0000879169-26-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer